Join

Compare · PM vs SGTX

PM vs SGTX

Side-by-side comparison of Philip Morris International Inc (PM) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PM and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • PM is the larger of the two at $274.40B, about 4718.3x SGTX ($58.2M).
  • PM has hit the wire 8 times in the past 4 weeks while SGTX has been quiet.
  • PM has more recent analyst coverage (25 ratings vs 8 for SGTX).
MetricPMSGTX
Company
Philip Morris International Inc
Sigilon Therapeutics Inc.
Price
$177.19+0.64%
$22.53-2.57%
Market cap
$274.40B
$58.2M
1M return
+3.64%
-
1Y return
-1.88%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
8
0
Recent ratings
25
8
PM

Philip Morris International Inc

Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

SGTX

Sigilon Therapeutics Inc.

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Latest PM

Latest SGTX